Drug General Information
Drug ID
D0L4WO
Former ID
DPR000186
Drug Name
SGN-19A
Drug Type
Antibody
Indication Hematologic malignancies [ICD9: 200-209; ICD10:C81-C86] Preclinical [551669]
Company
Seattle Genetics
Target and Pathway
Target(s) B-lymphocyte antigen CD19 Target Info [551669]
KEGG Pathway PI3K-Akt signaling pathway
Hematopoietic cell lineage
B cell receptor signaling pathway
Epstein-Barr virus infection
Primary immunodeficiency
NetPath Pathway IL-7 Signaling Pathway
PANTHER Pathway B cell activation
Pathway Interaction Database BCR signaling pathway
Reactome PIP3 activates AKT signaling
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Constitutive Signaling by Aberrant PI3K in Cancer
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
WikiPathways Human Complement System
Signaling by the B Cell Receptor (BCR)
PIP3 activates AKT signaling
B Cell Receptor Signaling Pathway
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
References
Ref 5516692011 Pipeline of Seattle Genetics.
Ref 5516692011 Pipeline of Seattle Genetics.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.